1 min
Vivalis CSO Interview - Embryonic Stem Cell Technology BioBusiness.TV, the podcast! ver2
-
- Investing
You are Watching:
Vivalis uses Embryonic Stem Cell Technology to Enable Vaccine and Antibody Production.
Chicken eggs revolutionized the production of vaccines. Could animal stem cells be the new chicken egg? Vivalis has created a technology platform based on embryonic stem cells that enables the production of vaccines and antibodies. Vivalis’ CSO Majid Mehtali is interviewed by Reni Benjamin, analyst at Rodman & Renshaw. The business model is based on technology licensing, with future ambitions for own product development. Majid and Reni review comparables, Vivalis’ cash position, Euronext vs. NASDAQ listing, and the potential for acquisitions.
This interview was conducted at the NASDAQ Marketsite, on July 17th, 2008, in New York City.
Featuring:
* Dr. Majid Mehtali, CSO of Vivalis Reni Benjamin, Managing Director & Senior Biotechnology Analyst at Rodman & Renshaw
* Jean-Loup Romet-Lemonne, President & CEO of BioBusiness.TV
DISCLAIMER:
BIOBUSINESS.TV IS AN INDEPENDENT MEDIA, AND A PLATFORM FOR THE EXCHANGE OF IDEAS AND OPINIONS. BIOBUSINESS.TV STRIVES TO ENHANCE THE QUALITY AND ACCESSIBILITY OF INDUSTRY DATA, AND TO DELIVER INFORMATION THAT INVESTORS AND EXECUTIVES CAN RELY UPON TO MAKE SOUND, INFORMED FINANCIAL AND MANAGERIAL DECISIONS. VIEWERS SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.
You are Watching:
Vivalis uses Embryonic Stem Cell Technology to Enable Vaccine and Antibody Production.
Chicken eggs revolutionized the production of vaccines. Could animal stem cells be the new chicken egg? Vivalis has created a technology platform based on embryonic stem cells that enables the production of vaccines and antibodies. Vivalis’ CSO Majid Mehtali is interviewed by Reni Benjamin, analyst at Rodman & Renshaw. The business model is based on technology licensing, with future ambitions for own product development. Majid and Reni review comparables, Vivalis’ cash position, Euronext vs. NASDAQ listing, and the potential for acquisitions.
This interview was conducted at the NASDAQ Marketsite, on July 17th, 2008, in New York City.
Featuring:
* Dr. Majid Mehtali, CSO of Vivalis Reni Benjamin, Managing Director & Senior Biotechnology Analyst at Rodman & Renshaw
* Jean-Loup Romet-Lemonne, President & CEO of BioBusiness.TV
DISCLAIMER:
BIOBUSINESS.TV IS AN INDEPENDENT MEDIA, AND A PLATFORM FOR THE EXCHANGE OF IDEAS AND OPINIONS. BIOBUSINESS.TV STRIVES TO ENHANCE THE QUALITY AND ACCESSIBILITY OF INDUSTRY DATA, AND TO DELIVER INFORMATION THAT INVESTORS AND EXECUTIVES CAN RELY UPON TO MAKE SOUND, INFORMED FINANCIAL AND MANAGERIAL DECISIONS. VIEWERS SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.
1 min